Steroid alternatives for managing eosinophilic lung diseases

References

• Carrington CB, Addington WW, Goff AM, et al., Chronic eosinophilic pneumonia. N Engl J Med. 280(15): 787–798. 1969.
   PubMed Web of Science ®Google Scholar
• Marchand E, Reynaud-Gaubert M, Lauque D, et al., Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine (Baltimore). 77(5): 299–312. 1998.
   PubMedGoogle Scholar
• Gaensler EA, Carrington CB. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema. AJR Am J Roentgenol. 1977;128(1):1–13.
   PubMed Web of Science ®Google Scholar
• Dejaegher P, Demedts M. Bronchoalveolar lavage in eosinophilic pneumonia before and during corticosteroid therapy. Am Rev Respir Dis. 1984;129(4):631–632.
   PubMedGoogle Scholar
• Bancal C, Sadoun D, Valeyre D, et al. [Chronic idiopathic eosinophilic pneumopathy. Carrington’s disease]. Presse Medicale Paris Fr 1983. 1989;18(34):1695–1698.
   Google Scholar
• Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest. 1993;103(1):162–165.
   PubMed Web of Science ®Google Scholar
• Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature. Medicine (Baltimore). 1988;67(3):154–162.
   PubMed Web of Science ®Google Scholar
• Dl P, Ec R. Chronic eosinophilic pneumonia (Carrington’s): a follow-up study. Mayo Clin Proc. 1978;53(2):73–78.
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Takayanagi N, Uozumi R, et al. The long-term clinical course of chronic eosinophilic pneumonia. Intern Med Tokyo Jpn. 2016;55(17):2373–2377.
   Google Scholar
• Eosinophilic Lung CV. Diseases. Clin Chest Med. 2016;37(3):535–556.
   PubMed Web of Science ®Google Scholar
• Holgate ST, Djukanović R, Casale T, et al. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2005;35(4):408–416.
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3):459–465.
   PubMed Web of Science ®Google Scholar
• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.
   PubMed Web of Science ®Google Scholar
• Rosenberg CE, Khoury P. Approach to eosinophilia presenting with pulmonary symptoms. Chest. 2021;159(2):507–516.
   PubMed Web of Science ®Google Scholar
• Nasser M, Thivolet-Béjui F, Sève P, et al. Lung-limited or lung-dominant variant of eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2020;8(6):2092–2095.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Oyama Y, Hozumi H, et al., Persistent impairment on spirometry in chronic eosinophilic pneumonia: a longitudinal observation study (Shizuoka-CEP study). Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 119(5): 422–428.e2. 2017.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev Off J Eur Respir Soc. 2020;29:155.
   Web of Science ®Google Scholar
• Samson M, Puéchal X, Devilliers H, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60–69.
   PubMed Web of Science ®Google Scholar
• Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ. 2020;369:m1067.
   PubMedGoogle Scholar
• Kuang FL, Fay MP, Ware J, et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. J Allergy Clin Immunol Pract. 2018;6(5):1518–1527.e5.
   PubMed Web of Science ®Google Scholar
• Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;39(8):1123–1128.
   PubMed Web of Science ®Google Scholar
• Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med. 1992;43(1):417–424.
   PubMedGoogle Scholar
• Pattern » I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) 9 May https://www.pneumotox.com/pattern/view/4/I.c/eosinophilic-pneumonia-pulmonary-infiltrates-and-eosinophil
   Google Scholar
• Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–1080.
   PubMed Web of Science ®Google Scholar
• Asano K, Hebisawa A, Ishiguro T, et al., New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 147(4): 1261–1268.e5. 2021.
   PubMed Web of Science ®Google Scholar
• Pneumotox. Pattern » I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia). cited 2021 May 9. https://www.pneumotox.com/pattern/view/4/I.c/eosinophilic-pneumonia-pulmonary-infiltrates-and-eosinophilia
   Google Scholar
• Chen LYC, Lai EJ, Collins DR, et al. A young woman with episodic angioedema, papilledema, and eosinophilia. Am J Hematol. 2010;85(2):124–127.
   PubMed Web of Science ®Google Scholar
• Chen LY, Wong PC, Noda S, et al. Polyclonal hyperviscosity syndrome in IgG4-related disease and associated conditions. Clin Case Rep. 2015;3(4):217–226.
   PubMed Web of Science ®Google Scholar
• Moussiegt A, Müller R, Ebbo M, et al. IgG4-related disease and hypereosinophilic syndrome: overlapping phenotypes. Autoimmun Rev. 2021;20(9):102889.
   PubMed Web of Science ®Google Scholar
• Muller R, Habert P, Ebbo M, et al. Thoracic involvement and imaging patterns in IgG4-related disease. Eur Respir Rev. 2021;30(162):210078.
   PubMed Web of Science ®Google Scholar
• Groh M, Lefèvre G, Ackermann F, et al. [Hypereosinophilic syndromes]. Rev Prat. 2019;69(7):767–773.
   PubMedGoogle Scholar
• Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39–44.
   PubMed Web of Science ®Google Scholar
• Marchand E, Etienne-Mastroianni B, Chanez P, et al. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Eur Respir J. 2003;22(1):8–13.
   PubMed Web of Science ®Google Scholar
• Oyama Y, Fujisawa T, Hashimoto D, et al., Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. Eur Respir J. 45(6): 1624–1631. 2015.
   PubMed Web of Science ®Google Scholar
• Ogbogu PU, Bochner BS, Butterfield JH, et al., Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 124(6): 1319–1325.e3. 2009.
   PubMed Web of Science ®Google Scholar
• Domingo C, Pomares X. Can omalizumab be effective in chronic eosinophilic pneumonia? Chest. 2013;143(1):274.
   PubMed Web of Science ®Google Scholar
• Kaya H, Gümüş S, Uçar E, et al. Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest. 2012;142(2):513–516.
   PubMed Web of Science ®Google Scholar
• Laviña-Soriano E, Ampuero-López A, Izquierdo-Alonso JL. Response to omalizumab in a patient with chronic eosinophilic pneumonia and poor response to corticosteroids. Arch Bronconeumol. 2017 December 16. DOI:https://doi.org/10.1016/j.arbres.2017.11.009.
   Google Scholar
• To M, Kono Y, Yamawaki S, et al. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(5):1746–1748.e1.
   PubMed Web of Science ®Google Scholar
• Kisling A, Jones J, Hixson C, Hostler D and Hostler J. (2020). Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. DIC, 9 1–7. https://doi.org/10.7573/dic.2020-5-3
   Google Scholar
• Ciuffreda M, Caruso C, Romano A, et al. Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: a case report. J Allergy Clin Immunol Pract. 2020;8(10):3640–3642.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Kurosawa M, Sutoh Y, et al. Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia. J Investig Allergol Clin Immunol. 2020;30(2):154–155.
   PubMed Web of Science ®Google Scholar
• Sarkis E, Patel S, Burns K, et al. Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia. J Asthma Off J Assoc Care Asthma. 2020;57(1):82–86.
   PubMed Web of Science ®Google Scholar
• Brenard E, Pilette C, Dahlqvist C, et al., Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia. Lung. 198(2): 355–360. 2020.
   PubMed Web of Science ®Google Scholar
• Roufosse F, Kahn J-E, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 September 18;146(6):1397–1405.
   PubMed Web of Science ®Google Scholar
• Yazawa S, Toyoshima M, Koda K, et al. Benralizumab as initial treatment for chronic eosinophilic pneumonia. Allergol Int Off J Jpn Soc Allergol. 2021;70(1):140–142.
   Google Scholar
• Isomoto K, Baba T, Sekine A, et al. Promising effects of benralizumab on chronic eosinophilic pneumonia. Intern Med Tokyo Jpn. 2020;59(9):1195–1198.
   Google Scholar
• Izumo T, Kuse N, Awano N, et al. Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia. Respir Med Case Rep. 2020;30:101062.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485.
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.e10.
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151.
   PubMed Web of Science ®Google Scholar
• Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag. 2019;15:869–875.
   PubMed Web of Science ®Google Scholar
• Descamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res. 2021;79:100821.
   PubMedGoogle Scholar
• Minakuchi M, Niimi A, Matsumoto H, et al. Chronic eosinophilic pneumonia: treatment with inhaled corticosteroids. Respir Int Rev Thorac Dis. 2003;70(4):362–366.
   Google Scholar
• Rosenberg M, Patterson R, Mintzer R, et al. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977;86(4):405–414.
   PubMed Web of Science ®Google Scholar
• Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol. 1988;81(4):646–650.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850–873.
   PubMed Web of Science ®Google Scholar
• Greenberger PA, Smith LJ, Hsu CC, et al. Analysis of bronchoalveolar lavage in allergic bronchopulmonary aspergillosis: divergent responses of antigen-specific antibodies and total IgE. J Allergy Clin Immunol. 1988;82(2):164–170.
   PubMed Web of Science ®Google Scholar
• Aubry MC, Fraser R. The role of bronchial biopsy and washing in the diagnosis of allergic bronchopulmonary aspergillosis. Mod Pathol Off J U S Can Acad Pathol Inc. 1998;11(7):607–611.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19(1):75.
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71(4):339–346.
   PubMed Web of Science ®Google Scholar
• Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med. 1986;146(5):916–918.
   PubMedGoogle Scholar
• Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110(5):685–692.
   PubMed Web of Science ®Google Scholar
• Tillie-Leblond I, Tonnel A-B. Allergic bronchopulmonary aspergillosis. Allergy. 2005;60(8):1004–1013.
   PubMed Web of Science ®Google Scholar
• Patterson R, Greenberger PA, Lee TM, et al. Prolonged evaluation of patients with corticosteroid-dependent asthma stage of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 1987;80(5):663–668.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Gupta D, Aggarwal AN, et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending a chest clinic in north India. Chest. 2006;130(2):442–448.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Aggarwal AN, Dhooria S, et al. A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016;47(2):490–498.
   PubMed Web of Science ®Google Scholar
• Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33(2):265–281.
   PubMed Web of Science ®Google Scholar
• Ueki S, Hebisawa A, Kitani M, et al. Allergic bronchopulmonary aspergillosis-A luminal hypereosinophilic disease with extracellular trap cell death. Front Immunol. 2018;9:2346.
   PubMed Web of Science ®Google Scholar
• Chauhan B, Knutsen AP, Hutcheson PS, et al. T cell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. J Clin Invest. 1996;97(10):2324–2331.
   PubMed Web of Science ®Google Scholar
• Fournier EC. Trial of ketoconazole in allergic bronchopulmonary aspergillosis. Thorax. 1987;42(10):831.
   PubMed Web of Science ®Google Scholar
• Shale DJ, Faux JA, Lane DJ. Trial of ketoconazole in non-invasive pulmonary aspergillosis. Thorax. 1987;42(1):26–31.
   PubMed Web of Science ®Google Scholar
• Ah H, Je P. Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax. 1968;23(5). https://pubmed.ncbi.nlm.nih.gov/5303008/. cited 2021 Mar 14.
   Web of Science ®Google Scholar
• Currie DC, Lueck C, Milburn HJ, et al. Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis. Thorax. 1990;45(6):447–450.
   PubMed Web of Science ®Google Scholar
• Crompton GK, Milne LJ. Treatment of bronchopulmonary aspergillosis with clotrimazole. Br J Dis Chest. 1973;67(4):301–307.
   PubMedGoogle Scholar
• Stark JE. Allergic pulmonary aspergillosis successfully treated with inhalations of nystatin. Report of a case. Dis Chest. 1967;51(1):96–99.
   PubMedGoogle Scholar
• Stevens DA, Schwartz HJ, Lee JY, et al., A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 342(11): 756–762. 2000.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018;153(3):656–664.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Dhooria S, Sehgal IS, et al. A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2018;52(3):3.
   Web of Science ®Google Scholar
• Voskamp AL, Gillman A, Symons K, et al., Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 3(2): 192–199. 2015.
   PubMed Web of Science ®Google Scholar
• Li J-X, Fan L-C, Li M-H, et al. Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature. Respir Med. 2017;122:33–42.
   PubMed Web of Science ®Google Scholar
• Terashima T, Shinozaki T, Iwami E, et al. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. BMC Pulm Med. 2018;21(1):18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870493/. [cited 2018 May 16]
   Google Scholar
• Schleich F, Vaia E-S, Pilette C, et al., Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian severe asthma registry and review of the literature. J Allergy Clin Immunol Pract. 8(7): 2412–2413.e2. 2020.
   PubMed Web of Science ®Google Scholar
• Soeda S, Kono Y, Tsuzuki R, et al. Allergic bronchopulmonary aspergillosis successfully treated with benralizumab. J Allergy Clin Immunol Pract. 2019;7(5):1633–1635.
   PubMed Web of Science ®Google Scholar
• Bernal-Rubio L, De-la-hoz Caballer B, Almonacid-Sánchez C, et al. Successful treatment of allergic bronchopulmonary aspergillosis with benralizumab in a patient who did not respond to omalizumab. J Investig Allergol Clin Immunol. 2020;30(5):378–379.
   PubMed Web of Science ®Google Scholar
• Dhariwal J, Hearn AP, Kavanagh JE, et al. Real-world effectiveness of anti-IL-5/5R therapy in severe atopic eosinophilic asthma with fungal sensitization. J Allergy Clin Immunol Pract. 2021;9(6):2315–2320.e1.
   PubMed Web of Science ®Google Scholar
• Altman MC, Lenington J, Bronson S, et al. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2017;5(4):1137–1139.
   PubMed Web of Science ®Google Scholar
• Ramonell RP, Lee FE-H, Swenson C, et al. Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series. J Allergy Clin Immunol Pract. 2020;8(2):742–743.
   PubMed Web of Science ®Google Scholar
• Mikura S, Saraya T, Yoshida Y, et al. Successful treatment of mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab. Intern Med Tokyo Jpn. 2021 March 1;60(17):2839–2842.
   Google Scholar
• Comarmond C, Pagnoux C, Khellaf M, et al., Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65(1): 270–281. 2013.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157 patients by the groupe d’etudes et de recherche sur les maladies orphelines pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev. 2017;16(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52(9):2926–2935.
   PubMed Web of Science ®Google Scholar
• Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429–1441.
   PubMedGoogle Scholar
• Leurs A, Chenivesse C, Lopez B, et al. C-Reactive protein as a diagnostic tool in differential diagnosis of hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2019;7(4):1347–1351.e3.
   PubMed Web of Science ®Google Scholar
• Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–553.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17–28.
   PubMed Web of Science ®Google Scholar
• Puéchal X, Pagnoux C, Baron G, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors:a randomized, controlled trial. Arthritis Rheumatol Hoboken NJ. 2017;69(11):2175–2186.
   PubMed Web of Science ®Google Scholar
• Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220.
   PubMed Web of Science ®Google Scholar
• Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
   PubMed Web of Science ®Google Scholar
• Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369(5):417–427.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771–1780.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis. 2016;75(2):396–401.
   PubMed Web of Science ®Google Scholar
• Emmi G, Rossi GM, Urban ML, et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2018;77(6):952–954.
   PubMed Web of Science ®Google Scholar
• Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019;5(1):e000905.
   PubMed Web of Science ®Google Scholar
• Menditto VG, Rossetti G, Olivari D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies. Rheumatol Oxf Engl. 2021;60(4):1640–1650.
   PubMed Web of Science ®Google Scholar
• Canzian A, Venhoff N, Urban ML, et al., Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study. Arthritis Rheumatol Hoboken NJ. 73(3): 498–503. 2021.
   PubMed Web of Science ®Google Scholar
• Kahn J-E, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(1):267–270.
   PubMed Web of Science ®Google Scholar
• Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155(5):341–343.
   PubMed Web of Science ®Google Scholar
• Kim S, Marigowda G, Oren E. Oren et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125(6):1336–1343.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Akuthota P, Jayne D, et al., Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 376(20): 1921–1932. 2017.
   PubMed Web of Science ®Google Scholar
• Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2021 February 4;126(6):696–701.e1.
   PubMed Web of Science ®Google Scholar
• Guntur VP, Manka LA, Denson JL, et al., Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 9(3): 1186–1193.e1. 2021.
   PubMed Web of Science ®Google Scholar
• Valent P, Klion AD, Horny H-P, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612.e9.
   PubMed Web of Science ®Google Scholar
• Rohmer J, Couteau-Chardon A, Trichereau J, et al. Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients. Am J Hematol. 2020;95(11):1314–1323.
   PubMed Web of Science ®Google Scholar
• Lefèvre G, Copin M-C, Staumont-Sallé D, et al. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore). 2014;93(17):255–266.
   PubMed Web of Science ®Google Scholar
• Carpentier C, Verbanck S, Schandené L, et al. Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients. Front Immunol. 2020;11:1765.
   PubMed Web of Science ®Google Scholar
• Dulohery MM, Patel RR, Schneider F, et al. Lung involvement in hypereosinophilic syndromes. Respir Med. 2011;105(1):114–121.
   PubMed Web of Science ®Google Scholar
• Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–1214.
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Giannouli S, Zoi C, et al. Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics. Medicine (Baltimore). 2007;86(6):344–354.
   PubMed Web of Science ®Google Scholar
• Coutant G, Blétry O, Prin L, et al. [Treatment of hypereosinophilic syndromes of myeloproliferative expression with the combination of hydroxyurea and interferon alpha. Apropos of 7 cases]. Ann Med Internet (Paris). 1993;144(4):243–250.
   PubMedGoogle Scholar
• Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994;121(9):648–653.
   PubMed Web of Science ®Google Scholar
• Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol. 1998;77(4):161–164.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9):2012–2018.
   PubMed Web of Science ®Google Scholar
• Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res. 2012;36(2):192–197.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al., Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 358(12): 1215–1228. 2008.
   PubMed Web of Science ®Google Scholar
• Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336–1346.
   PubMed Web of Science ®Google Scholar
• Abisror N, Mekinian A, Dechartres A, et al. Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich’s syndrome): frequency, clinical implication and prognosis. J Am Acad Dermatol. 2019 February 6. DOI:https://doi.org/10.1016/j.jaad.2019.02.001.
   Google Scholar
• Baulier G, Asli B, Galicier L, et al. Romidepsin is an effective and well-tolerated therapy in CD3-CD4+ lymphocyte-variant hypereosinophilic syndrome: a case report. J Allergy Clin Immunol Pract. 2019;7(8):2885–2887.e1.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Chung C, William BM. Dramatic and durable responses to romidepsin in two patients with the lymphocytic variant of hypereosinophilic syndrome. Clin Lymphoma Myeloma Leuk. 2020;20(3):e128–e130. e128-e130.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Peterson KA, Murray JA, et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N Engl J Med. 2020;383(17):1624–1634.
   PubMed Web of Science ®Google Scholar
• Oliver ET, Chichester K, Devine K, et al. Effects of an Oral CRTh2 Antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria. Int Arch Allergy Immunol. 2019;179(1):21–30.
   PubMed Web of Science ®Google Scholar
• Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016;4(9):699–707.
   PubMed Web of Science ®Google Scholar
• Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809.
   PubMed Web of Science ®Google Scholar